Unlock stock picks and a broker-level newsfeed that powers Wall Street.

Frankfurt - Delayed Quote EUR

Neural Therapeutics Inc. (M6B.F)

0.0179
0.0000
(0.00%)
As of March 31 at 3:29:01 PM GMT+2. Market Open.
Loading Chart for M6B.F
  • Previous Close 0.0179
  • Open 0.0179
  • Bid 0.0200 x --
  • Ask 0.0232 x --
  • Day's Range 0.0179 - 0.0179
  • 52 Week Range 0.0145 - 0.0244
  • Volume 10,994
  • Avg. Volume 2,512
  • Market Cap (intraday) 1.999M
  • Beta (5Y Monthly) --
  • PE Ratio (TTM) --
  • EPS (TTM) -0.0000
  • Earnings Date --
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est --

Neural Therapeutics Inc., a drug discovery company, focuses on plant-based active substances. It focuses on San Pedro, a cactus containing mescaline and delivers over-the-counter dietary supplements and psychedelic-based therapeutic medicines to treat serious mental ailments. Neural Therapeutics Inc. was formerly known as Psychedelic Science Corp. and changed its name to Neural Therapeutics Inc. in November 2021. The company was incorporated in 2020 and is headquartered in Toronto, Canada.

www.neuraltherapeutics.ca

--

Full Time Employees

July 31

Fiscal Year Ends

Recent News: M6B.F

View More

Performance Overview: M6B.F

Trailing total returns as of 4/22/2025, which may include dividends or other distributions. Benchmark is S&P/TSX Composite index (^GSPTSE) .

YTD Return

M6B.F
0.56%
S&P/TSX Composite index (^GSPTSE)
1.28%

1-Year Return

M6B.F
0.56%
S&P/TSX Composite index (^GSPTSE)
11.13%

3-Year Return

M6B.F
0.56%
S&P/TSX Composite index (^GSPTSE)
14.72%

5-Year Return

M6B.F
0.56%
S&P/TSX Composite index (^GSPTSE)
70.11%

Compare To: M6B.F

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: M6B.F

View More

Valuation Measures

Annual
As of 4/17/2025
  • Market Cap

    1.97M

  • Enterprise Value

    1.93M

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    --

  • Price/Book (mrq)

    --

  • Enterprise Value/Revenue

    --

  • Enterprise Value/EBITDA

    --

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    0.00%

  • Return on Assets (ttm)

    -102.00%

  • Return on Equity (ttm)

    --

  • Revenue (ttm)

    --

  • Net Income Avi to Common (ttm)

    -548.15k

  • Diluted EPS (ttm)

    -0.0000

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    546.32k

  • Total Debt/Equity (mrq)

    --

  • Levered Free Cash Flow (ttm)

    -415.88k

Research Analysis: M6B.F

View More

Company Insights: M6B.F

Research Reports: M6B.F

View More